Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 19, 2018

Primary Completion Date

August 3, 2026

Study Completion Date

August 3, 2026

Conditions

Sickle Cell Disease

Interventions

DRUG

Plerixafor

Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)

Trial Locations (1)

City of Hope Medical Center, Duarte

All Listed Sponsors

lead

City of Hope Medical Center

OTHER